RT Journal Article SR Electronic T1 Antiretroviral therapy associated lipodystrophy; learning from the past JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.18.21255695 DO 10.1101/2021.04.18.21255695 A1 Senai Goitom Sereke A1 Semhar Eyob Berhe A1 Felix Bongomin YR 2021 UL http://medrxiv.org/content/early/2021/04/22/2021.04.18.21255695.abstract AB Background With the introduction of effective antiretroviral therapy (ART), descriptions of body shape abnormalities, such as central fat accumulation and peripheral fat loss emerged among persons living with human immunodeficiency virus (HIV). We aimed to determine the prevalence of lipodystrophy and associated risk factors among patients on ART at Orotta National Referral Hospital (ONRH), Asmara, Eritrea.Methods A single center, retrospective study was conducted at the ONRH, reviewing records of HIV-infected patients commenced on ART between January 2007 and December 2012.Results Records of 250 eligible patients were reviewed. Most were female (59.2%, n=148) with a median age of 35 (IQR-20-63) years. Forty-three (17.2%) participants had body fat abnormalities. 42 (97.6%) had lipoatrophy and 1 (2.4%) buffalo hump. Of the 43 patients with lipodystrophy 34 (79%) were on Stavudine (d4T)/Lamivudine (3TC)/Nevirapine (NVP) regimen, 6 (14%) on Zidovudine (AZT)/3TC/NVP, 2 (4.7%) on d4T/3TC/Efavirenz (EFV) and 1(2.3%) on AZT, 3TC, EFV. EFV-based regimen was significantly associated with lipodystrophy (p< 0.01).Conclusion We report a high prevalence of lipodystrophy. Four drug regimens were incriminated in the development of lipodystrophy. EFV-based regimen was significantly associated with the lipodystrophy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. Orotta school of medicine 2. the Research ethics and Protocol review committee of the Eritrean ministry of healthAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe information used and/or analyzed during this manuscript is available from the corresponding author on reasonable request.3TCLamivudineAIDSAcquired Immunodeficiency Syndrome.ABCAbacavirARTAntiretroviral Therapy/ TreatmentAtv/rAtazanvir/ritonavirAZTZidovudineBMIBody Mass IndexCTComputed TomographyDEXADual-Energy X-ray Absorptiometryd4TStavudineddIDidanosineEFVEfavirenzELISAEnzyme-Linked ImmunoSorbent Assay.FTCEmtricitabineHIVHuman Immunodeficiency Virus.HAARTHighly Active Antiretroviral Therapy/ TreatmentLPV/rLopinavir/ritonavirMoHMinistry of HealthMACSMulticenter AIDS Cohort StudyMRIMagnetic Resonance Imaging.NVPNevirapineNRTIsNucleoside or nucleotide Reverse Transcriptase InhibitorNNRTINon-Nucleoside Reverse Transcriptase InhibitorPIProtease InhibitorSJSStevens-Johnson SyndromeWHOworld health organization